PHARMACOKINETIC AND PHARMACODYNAMIC ASPECTS OF POLYPEPTIDE DELIVERY

被引:31
作者
MAZER, NA
机构
[1] TheraTech, Inc. and Department of Pharmaceutics, University of Utah, Salt Lake City
关键词
input function; modelling; pharmacodynamics; pharmacokinetics; polypeptides;
D O I
10.1016/0168-3659(90)90146-K
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The rational design and development of drug delivery systems for polypeptide compounds requires a quantitative understanding of the pharmacokinetics (PK) and pharmacodynamics (PD) of the compound in the intended therapeutic indication. In particular it is necessary to define the characteristics of the input function, i.e. the rate and time course of systemic drug input, that will maximize the therapeutic effect, minimize unwanted side effects and prevent tachyphylaxis from occurring. This paper reviews the general concepts of input function, PK and PD, and illustrates these concepts using two examples from the literature: (1) Sandoz compound SMS 201-995 and (2) gonadotropin-releasing hormone (GnRH). For SMS 201-995, a continuous (zero-order) input function is shown to be optimal for suppressing growth hormone secretion in the treatment of acromegaly. For GnRH, a pulsatile input function is optimal for stimulating pituitary gonadotropin secretion, whereas continuous input leads to a paradoxical suppression of gonadotropin secretion. These examples further illustrate the types of novel experimental approaches, using programmable infusion pumps, that are needed for investigating the relationship between PK and PD, and for defining the optimal input function experimentally. In addition, we show how mathematical models may be used to describe the interrelationships between input function, PK and PD. For SMS 201-995, a model based on the "effect compartment" concept offers a self-consistent description of the linkage between PK and PD and provides insight into the superiority of continuous input in the treatment of acromegaly. For GnRH, the complex relationship between input function and gonadotropin secretion is modelled on the basis of heuristic concepts that relate the time-averaged occupancy of the GnRH-receptors (by GnRH) to the expression of GnRH-receptors by the pituitary (i.e. down and up regulation). Together these examples illustrate the diversity of input functions that will be needed in polypeptide delivery and the novel experimental and theoretical approaches required for defining them. © 1990.
引用
收藏
页码:343 / 356
页数:14
相关论文
共 50 条
  • [41] Pharmacokinetic and pharmacodynamic considerations of cephalosporin use in children
    Tauzin, Manon
    Ouldali, Naim
    Bechet, Stephane
    Caeymaex, Laurence
    Cohen, Robert
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (11) : 869 - 880
  • [42] Clarithromycin: Pharmacokinetic and pharmacodynamic interrelationships and dosage regimen
    Periti, P
    Mazzei, T
    JOURNAL OF CHEMOTHERAPY, 1999, 11 (01) : 11 - 27
  • [43] Pharmacokinetic and pharmacodynamic concepts for an interpretative reading of the antibiogram
    Soriano, F
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2002, 20 (08): : 407 - 412
  • [44] Pharmacokinetic-pharmacodynamic model for educational simulations
    van Meurs, WL
    Nikkelen, E
    Good, ML
    IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, 1998, 45 (05) : 582 - 590
  • [45] Dobutamine Alters the Pharmacokinetic and Pharmacodynamic Behavior of Esmolol
    Krumpl, Guenther
    Ulc, Ivan
    Trebs, Michaela
    Hodisch, Juri
    Kadlecova, Pavla
    Husch, Bernhard
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (12)
  • [46] FLUNIXIN IN THE CAT - A PHARMACODYNAMIC, PHARMACOKINETIC AND TOXICOLOGICAL STUDY
    TAYLOR, PM
    WINNARD, JG
    JEFFERIES, R
    LEES, P
    BRITISH VETERINARY JOURNAL, 1994, 150 (03): : 253 - 262
  • [47] The use of transgenic mice in pharmacokinetic and pharmacodynamic studies
    Elmquist, WF
    Miller, DW
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 90 (04) : 422 - 435
  • [48] Pharmacokinetic and pharmacodynamic studies of supaglutide in rats and monkeys
    Liao, Yijing
    Ma, Anran
    Wang, Zhihong
    Zhou, Yue
    Liu, Lin
    Zhang, Na
    Zhang, Li
    Prud'homme, Gerald J.
    Wang, Qinghua
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 175
  • [49] NICOTINE HABITUATION AND DEPENDENCE - A PHARMACOKINETIC AND PHARMACODYNAMIC APPROACH
    PORCHET, HC
    SEMAINE DES HOPITAUX, 1991, 67 (28-29): : 1309 - 1319
  • [50] Pharmacokinetic/pharmacodynamic considerations for epilepsy - depression comorbidities
    Banach, Monika
    Poplawska, Monika
    Blaszczyk, Barbara
    Borowicz, Kinga K.
    Czuczwar, Stanislaw J.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (09) : 1067 - 1080